RA
MCID: RHM011
MIFTS: 81

Rheumatoid Arthritis (RA)

Categories: Bone diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Rheumatoid Arthritis

MalaCards integrated aliases for Rheumatoid Arthritis:

Name: Rheumatoid Arthritis 56 12 74 25 73 36 29 54 6 42 3 15 37 62 17 71
Ra 56 25 73 3
Arthritis, Rheumatoid 25 43 39
Rheumatoid Arthritis, Susceptibility to 56 13
Arthritis or Polyarthritis, Rheumatic 12
Atrophic Arthritis 12

Characteristics:

OMIM:

56
Inheritance:
unproved inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:7148
OMIM 56 180300
KEGG 36 H00630
ICD9CM 34 714.0
MeSH 43 D001172
NCIt 49 C2884
SNOMED-CT 67 69896004
MedGen 41 C0003873
UMLS 71 C0003873

Summaries for Rheumatoid Arthritis

Genetics Home Reference : 25 Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a symmetrical pattern; for example, if joints in the hand are affected, both hands tend to be involved. People with rheumatoid arthritis often report that their joint pain and stiffness is worse when getting out of bed in the morning or after a long rest. Rheumatoid arthritis can also cause inflammation of other tissues and organs, including the eyes, lungs, and blood vessels. Additional signs and symptoms of the condition can include a loss of energy, a low fever, weight loss, and a shortage of red blood cells (anemia). Some affected individuals develop rheumatoid nodules, which are firm lumps of noncancerous tissue that can grow under the skin and elsewhere in the body. The signs and symptoms of rheumatoid arthritis usually appear in mid- to late adulthood. Many affected people have episodes of symptoms (flares) followed by periods with no symptoms (remissions) for the rest of their lives. In severe cases, affected individuals have continuous health problems related to the disease for many years. The abnormal inflammation can lead to severe joint damage, which limits movement and can cause significant disability.

MalaCards based summary : Rheumatoid Arthritis, also known as ra, is related to arthritis and palindromic rheumatism, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Rheumatoid Arthritis is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Rheumatoid arthritis and NF-kappaB Signaling. The drugs Dimethyl fumarate and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include Cartilage, joint and bone, and related phenotypes are abnormality of the nervous system and abnormality of the immune system

Disease Ontology : 12 An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint.

OMIM : 56 Rheumatoid arthritis is an inflammatory disease, primarily of the joints, with autoimmune features and a complex genetic component. (180300)

MedlinePlus : 42 Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness and loss of function in your joints. It can affect any joint but is common in the wrist and fingers. More women than men get rheumatoid arthritis. It often starts in middle age and is most common in older people. You might have the disease for only a short time, or symptoms might come and go. The severe form can last a lifetime. Rheumatoid arthritis is different from osteoarthritis, the common arthritis that often comes with older age. RA can affect body parts besides joints, such as your eyes, mouth and lungs. RA is an autoimmune disease, which means the arthritis results from your immune system attacking your body's own tissues. No one knows what causes rheumatoid arthritis. Genes, environment, and hormones might contribute. Treatments include medicine, lifestyle changes, and surgery. These can slow or stop joint damage and reduce pain and swelling. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). RA can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

KEGG : 36 Rheumatoid arthritis (RA) is a common autoimmune disease that primarily manifests as chronic inflammatory arthropathy. Persistent synovitis leads to cartilage destruction, bone erosions and periarticular decalcification, subsequently resulting in impaired joint function. It is more common between the ages of 35 and 50 years, affecting three times more women than men. Susceptibility to RA is genetically determined with multiple genes contributing. Inheritance of HLA DRB1 alleles encoding a distinctive five-amino-acid sequence known as the "shared epitope" (SE) is the best characterized genetic risk factor. The mechanism by which the SE alleles contribute to the development of RA is not very clear. It has been postulated that the presence of these conserved sequences in the antigen-binding groove alters the way antigenic peptides are bound to and presented to T-cell lymphocytes. This, in turn, may trigger abnormal immune responses and lead to RA.

UniProtKB/Swiss-Prot : 73 Rheumatoid arthritis: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

PubMed Health : 62 About rheumatoid arthritis: There are many different rheumatic diseases, but rheumatoid arthritis is probably the most common. In rheumatoid arthritis, people usually have several permanently inflamed joints. This causes the joints to gradually become deformed and stiff. Over time the muscles also weaken. Someone with advanced rheumatoid arthritis may have difficulties with simple tasks such as washing themselves, eating with a knife and fork, or buttoning up a shirt. Other symptoms such as pain and fatigue can be very troublesome too. This disease can also affect other parts of the body, like the blood vessels or certain organs. Rheumatoid arthritis usually gradually worsens over the course of many years. Various treatments can relieve the pain and slow the progression of the disease. Early diagnosis and treatment can help to prevent damage to the joints.

Wikipedia : 74 Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically... more...

Related Diseases for Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2346)
# Related Disease Score Top Affiliating Genes
1 arthritis 35.0 PTPN22 PADI4 IRF5 IL10 CIITA
2 palindromic rheumatism 33.8 PTPN22 PADI4
3 autoimmune disease 33.7 PTPN22 PADI4 MIR146A IRF5 IL10 CIITA
4 rheumatic disease 33.2 PADI4 MIR155 MIR146A IL10
5 crohn's disease 32.5 SLC22A4 PTPN22 IRF5 IL10
6 systemic lupus erythematosus 32.4 PTPN22 PADI4 MIR155 MIR150 MIR146A MALAT1
7 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.4 PTPN22 IL10
8 bone inflammation disease 32.4 PTPN22 PADI4 MIR155 MIR146A IL10
9 lymphoproliferative syndrome 31.9 MIR146A IL10 CD244
10 multiple sclerosis 31.7 PTPN22 PADI4 MIR155 IL10 CIITA
11 polymyositis 31.7 MIR155 MIR132
12 b-cell lymphoma 31.4 MIR155 MALAT1 HOTAIR CIITA
13 diffuse large b-cell lymphoma 31.2 MIR155 MIR150 IL10 HOTAIR
14 thyroid cancer, nonmedullary, 1 30.6 MIR146A MALAT1 HOTAIR H19
15 leukemia, chronic lymphocytic 30.3 MIR155 MIR150 MIR146A MIR132 IL10
16 pancreatic ductal adenocarcinoma 30.2 UCA1 MIR155 MIR150 MIR146A MALAT1 HOTAIR
17 nervous system disease 30.2 MIR155 MIR150 MIR146A MIR132
18 myeloma, multiple 30.0 UCA1 MIR155 MALAT1 IL10 HOTAIR H19
19 squamous cell carcinoma, head and neck 29.7 MIR155 MIR150 MIR132 HOTAIR H19
20 central nervous system disease 29.7 MIR155 MIR150 MIR146A MIR132 H19
21 laryngeal squamous cell carcinoma 29.6 MALAT1 HOTAIR H19
22 kidney cancer 29.4 MIR150 MALAT1 HOTAIR H19
23 pituitary adenoma 29.3 MIR132 MALAT1 HOTAIR H19
24 leukemia, acute myeloid 29.3 UCA1 MIR155 MIR150 MIR146A MALAT1 IL10
25 thyroid gland cancer 29.2 UCA1 MIR146A MALAT1 HOTAIR H19
26 glioma 29.1 ZFAS1 UCA1 MALAT1 HOTAIR H19
27 osteogenic sarcoma 29.0 UCA1 MALAT1 HOTAIR H19
28 cervical cancer 29.0 UCA1 MIR155 MIR146A MIR132 MALAT1 IL10
29 gastrointestinal system cancer 28.9 MIR155 MIR150 MIR146A MALAT1 HOTAIR H19
30 renal cell carcinoma, nonpapillary 28.8 UCA1 MIR155 MIR150 MALAT1 HOTAIR H19
31 bladder cancer 28.8 ZFAS1 UCA1 MIR146A MALAT1 HOTAIR H19
32 esophageal cancer 28.7 UCA1 MIR155 MIR146A MALAT1 IL10 HOTAIR
33 gallbladder cancer 28.6 UCA1 MALAT1 HOTAIR H19
34 oral squamous cell carcinoma 28.4 UCA1 MIR155 MIR146A MIR132 MALAT1 HOTAIR
35 hepatocellular carcinoma 27.9 ZFAS1 UCA1 MIR155 MIR150 MIR146A MIR132
36 ovarian cancer 27.5 ZFAS1 UCA1 MIR155 MIR150 MIR146A MALAT1
37 juvenile rheumatoid arthritis 13.1
38 rheumatoid arthritis, systemic juvenile 12.9
39 rheumatoid arthritis interstitial lung disease 12.9
40 ras-associated autoimmune leukoproliferative disorder 12.8
41 felty syndrome 12.5
42 sjogren syndrome 12.0
43 polyarticular onset juvenile idiopathic arthritis 11.9
44 rheumatoid vasculitis 11.9
45 arthropathy, progressive pseudorheumatoid, of childhood 11.9
46 adult-onset still's disease 11.9
47 carpal tunnel syndrome 11.8
48 fibromyalgia 11.8
49 systemic scleroderma 11.8
50 spondyloarthropathy 1 11.8

Comorbidity relations with Rheumatoid Arthritis via Phenotypic Disease Network (PDN): (show all 32)


Active Peptic Ulcer Disease Acute Cystitis
Bronchiectasis Bronchitis
Chronic Rheumatic Pericarditis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Esophagitis Felty Syndrome
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Idiopathic Interstitial Pneumonia Immune Deficiency Disease
Iron Deficiency Anemia Mononeuropathy of the Median Nerve, Mild
Neutropenia Olecranon Bursitis
Oral Candidiasis Osteoarthritis
Osteoporosis Perforated Corneal Ulcer
Postinflammatory Pulmonary Fibrosis Premature Ovarian Failure 7
Protein-Energy Malnutrition Scleritis
Sjogren Syndrome Spondyloarthropathy 1
Systemic Lupus Erythematosus Temporal Arteritis

Graphical network of the top 20 diseases related to Rheumatoid Arthritis:



Diseases related to Rheumatoid Arthritis

Symptoms & Phenotypes for Rheumatoid Arthritis

Human phenotypes related to Rheumatoid Arthritis:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 abnormality of the immune system 31 HP:0002715
3 vasculitis 31 HP:0002633
4 abnormality of the respiratory system 31 HP:0002086
5 abnormality of blood and blood-forming tissues 31 HP:0001871
6 rheumatoid arthritis 31 HP:0001370

Symptoms via clinical synopsis from OMIM:

56
Joints:
rheumatoid arthritis

Limbs:
rheumatoid nodules

Vascular:
rheumatoid vasculitis

Neuro:
rheumatoid vasculitic mononeuritis

Immunology:
hla-drb1 association

Pulm:
rheumatoid lung disease

Heme:
felty syndrome

Clinical features from OMIM:

180300

UMLS symptoms related to Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

Drugs & Therapeutics for Rheumatoid Arthritis

PubMed Health treatment related to Rheumatoid Arthritis: 62

Rheumatoid arthritis is treated with both medication and non-drug approaches, such as physiotherapy . There are also various support aids available for making everyday tasks easier. Which of these treatments are suitable options will depend on, for example, how severe the inflammation and the symptoms are, how advanced the disease is, the expected progression of the disease – and how well previous treatments have worked. Medication can reduce inflammation and help keep the disease from getting worse, relieve symptoms like pain and swelling, and help people move their joints more easily again, or at least maintain joint flexibility for as long as possible. There is currently no cure for rheumatoid arthritis . Physiotherapy and sports can help improve or maintain flexibility, strength and joint function. Many types of sports are suitable for people who have rheumatoid arthritis , including cycling, brisk walking, dancing, aerobics, strength training , swimming and water aerobics. Occupational therapy can be used to maintain your flexibility and hand strength, and to learn how to cope with rheumatoid arthritis in everyday life. Psychological treatments are also sometimes used to help relieve pain and minimize the impact it has on everyday life. They are also intended to help relieve disease-related anxiety and depression that some people develop. Support aids are designed to help compensate for physical limitations and help with daily activities. These include orthopedic shoe inserts, grabbing aids and specially designed cutlery.

Drugs for Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 697)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Denosumab Approved Phase 4 615258-40-7
6
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
7
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
8
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Ticagrelor Approved Phase 4 274693-27-5 9871419
13
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
17
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
18
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
19 Orange Approved Phase 4
20
Aceclofenac Approved, Investigational Phase 4 89796-99-6
21
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
24
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
25
Pheniramine Approved Phase 4 86-21-5 4761
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
28
alemtuzumab Approved, Investigational Phase 4 216503-57-0
29
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
30
Morphine Approved, Investigational Phase 4 57-27-2 5288826
31
Codeine Approved, Illicit Phase 4 76-57-3 5284371
32
Pancrelipase Approved, Investigational Phase 4 53608-75-6
33 Strawberry Approved Phase 4
34 Artichoke Approved Phase 4
35
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
36
Anthralin Approved Phase 4 1143-38-0
37
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
38
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
41
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
42 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Certolizumab pegol Approved Phase 4 428863-50-7
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
47
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
48
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
49
Racepinephrine Approved Phase 4 329-65-7 838
50
carbamide peroxide Approved Phase 4 124-43-6

Interventional clinical trials:

(show top 50) (show all 2997)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
4 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
5 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
6 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
7 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
8 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
9 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
10 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
11 Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity Unknown status NCT02770794 Phase 4 Infliximab
12 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
13 A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis Unknown status NCT02780323 Phase 4 CELBESTA®;CELEBREX®;CELEBREX® placebo;CELBESTA® placebo
14 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
15 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
16 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
17 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
18 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
19 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
20 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
21 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
22 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
23 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
24 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
25 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
26 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
27 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
28 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
29 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
30 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
31 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
32 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
33 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
34 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
35 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
36 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
37 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
38 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Unknown status NCT02437461 Phase 4 Triamcinolone hexacetonide
39 A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis Unknown status NCT00808496 Phase 4
40 Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase Unknown status NCT00525993 Phase 4 etoricoxib 90mg 14 days;etoricoxib 60mg daily for 14 days
41 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
42 A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA) Completed NCT01554917 Phase 4 Iguratimod
43 Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO) Completed NCT00234897 Phase 4 adalimumab
44 A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate Completed NCT00913458 Phase 4 etanercept
45 An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs Completed NCT01511003 Phase 4 Tacrolimus
46 An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects Completed NCT00252668 Phase 4 Etanercept;Methotrexate
47 A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy Completed NCT00244556 Phase 4 Methotrexate plus ENBREL or ENBREL alone
48 Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study Completed NCT01224418 Phase 4 Tacrolimus
49 Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study Completed NCT01224041 Phase 4 Tacrolimus
50 Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders Completed NCT00132418 Phase 4 Enbrel;Placebo

Search NIH Clinical Center for Rheumatoid Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ACETYLSALICYLATE SODIUM
adalimumab
anakinra
Aspirin
ASPIRIN PWDR
Auranofin
Aurothioglucose
Azathioprine
Captopril
celecoxib
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
choline salicylate
Cyclosporine
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Enalapril
Enalapril Maleate
Enalaprilat
Etanercept
Etodolac
Fenoprofen
Fenoprofen Calcium
Fish Oils
Flurbiprofen
Flurbiprofen sodium
Gold
Gold Sodium Thiomalate
Hydroxychloroquine
Hydroxychloroquine Sulfate
Ibuprofen
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Ketoprofen
KETOPROFEN PWDR
leflunomide
Methotrexate
Methotrexate Sodium
nabumetone
Naproxen
Naproxen sodium
oxaprozin
Penicillamine
Piroxicam
solufenum
Sulfasalazine
Sulindac
Thalidomide
tocilizumab
tofacitinib
Tolmetin
Tolmetin Sodium
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Rheumatoid Arthritis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: arthritis, rheumatoid

Genetic Tests for Rheumatoid Arthritis

Genetic tests related to Rheumatoid Arthritis:

# Genetic test Affiliating Genes
1 Rheumatoid Arthritis 29 CD244 CIITA IL10 NFKBIL1 PADI4 PTPN22 SLC22A4

Anatomical Context for Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Rheumatoid Arthritis:

40
Bone, T Cells, Lung, Testes, Endothelial, B Cells, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Rheumatoid Arthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease

Publications for Rheumatoid Arthritis

Articles related to Rheumatoid Arthritis:

(show top 50) (show all 33401)
# Title Authors PMID Year
1
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. 56 6 54
19898480 2009
2
Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. 56 6 61
18794858 2008
3
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. 54 6 56
17599733 2007
4
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. 54 6 56
15208781 2004
5
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 56 6
17554300 2007
6
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. 56 6
17436241 2007
7
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. 56 6
14608356 2003
8
Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. 6 56
12509789 2003
9
A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. 54 56 61
20453841 2010
10
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. 56 61 54
18794853 2008
11
BLyS and APRIL in rheumatoid arthritis. 54 61 56
16239971 2005
12
Genetics of rheumatoid arthritis contributes to biology and drug discovery. 61 56
24390342 2014
13
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. 61 56
20453842 2010
14
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. 61 56
19898481 2009
15
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. 54 56
19503088 2009
16
Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. 54 56
18759272 2008
17
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. 54 46 61
18759964 2008
18
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. 56 61
17982456 2007
19
Rheumatoid arthritis association at 6q23. 61 56
17982455 2007
20
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. 56 61
17804836 2007
21
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. 61 56
17804842 2007
22
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. 6 54
17170052 2007
23
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. 54 6
16273109 2005
24
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. 56 54
16175503 2005
25
4-1BB-mediated immunotherapy of rheumatoid arthritis. 61 56
15448685 2004
26
Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. 54 56
14558082 2003
27
Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. 56 54
12847677 2003
28
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. 56 54
11477412 2001
29
Rheumatoid arthritis. 56 61
8616886 1996
30
Genetic epidemiology of rheumatoid arthritis. 61 56
7611283 1995
31
HLA-linked rheumatoid arthritis. 56 61
7942852 1994
32
Heredofamilial deficiency of monocyte esterase in patients with rheumatoid arthritis. 56 61
1616336 1992
33
Different HLA-D associations in adult and juvenile rheumatoid arthritis. 61 56
762241 1979
34
FAMILIAL FACTORS IN RHEUMATOID ARTHRITIS. 61 56
14120603 1964
35
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. 56
25324392 2014
36
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. 56
24786080 2014
37
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. 56
22290871 2012
38
The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. 6
21841778 2011
39
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. 56
21211616 2011
40
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. 61 46
20840794 2010
41
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. 56
20360734 2010
42
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. 56
20110505 2010
43
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. 56
19359276 2009
44
Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. 56
19417005 2009
45
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. 6
19430480 2009
46
Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. 6
19265110 2009
47
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. 6
18978792 2008
48
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. 6
18301444 2008
49
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. 6
18063667 2008
50
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. 6
17878369 2007